758P Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC)
Johannes Breyer(University of Regensburg), Ademi Santiago-Walker, Wolfgang Otto(University of Regensburg), Ramesh Sundaram(Janssen (United States)), Arndt Hartmann(Universitätsklinikum Erlangen), Roman Mayr(Ospedale di Bolzano), Mahadi Baig(Johnson & Johnson (United States)), Christian Bolenz(Heidelberg University), Manish Monga(Institut Gustave Roussy), Aaron Galluzzi(IQVIA (United States)), Markus Eckstein(Friedrich-Alexander-Universität Erlangen-Nürnberg), Sebastian Eidt(St. Elisabeth-Hospital Bochum), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), RM Wirtz, M. Bürger(Klinik und Poliklinik für Urologie), Philipp Erben(Heidelberg University)
Cited by 1
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
|The Lancet Oncology|2017|431
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
|Leukemia|2012|417
Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis
|The American Journal of Surgical Pathology|2005|411